<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>L-Asparaginase is the major induction-phase agent for treatment of <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (ALL) and an important adjuvant in treatment of non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL) </plain></SENT>
<SENT sid="1" pm="."><plain>However, L-asparaginase-induced disturbances of clotting homeostasis may result in <z:mp ids='MP_0005048'>thrombosis</z:mp> or <z:mp ids='MP_0001914'>hemorrhage</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>Thrombotic occlusion of small cerebral veins has been reported in patients with ALL treated with this agent, but have not been described in NHL patients or those treated with the long-acting synthetic congener, pegaspargase </plain></SENT>
<SENT sid="3" pm="."><plain>We report a 16-year-old boy with NHL who developed a focal motor <z:hpo ids='HP_0001250'>seizure</z:hpo> 15 min after receiving intravenous pegaspargase </plain></SENT>
<SENT sid="4" pm="."><plain>MRI of the brain demonstrated multiple cortical and <z:e sem="disease" ids="C0871456" disease_type="Disease or Syndrome" abbrv="">subcortical lesions</z:e> that most likely represented focal <z:hpo ids='HP_0002181'>brain edema</z:hpo> due to thrombotic venous occlusion, which improved remarkably within 3 days and completely resolved within 3 weeks without specific intervention or permanent clinical consequences </plain></SENT>
<SENT sid="5" pm="."><plain>This process must be considered when such changes are detected in NHL patients </plain></SENT>
</text></document>